Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer

Xiaoyan Wang, Robert J. Hickey, Linda H. Malkas, Michael Koch, Lang Li, Shaobo Zhang, George Sandusky, David Grignon, John Eble, Liang Cheng

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND. Proliferating cell nuclear antigen (PCNA) plays an important role in DNA replication and repair. The expression and potential utility of this marker in prostatic neoplasia is uncertain. With the development of this new caPCNA selective antibody, we explored the potential utility of this marker in prostate cancer. METHODS. Using a traditional primary Fab2′ rabbit anti-caPCNA antibody-HRP conjugated secondary anti-Fab2′ antibody format, the expression of the caPCNA was analyzed in prostate tissue from 89 radical prostatectomy specimens. The caPCNA expression was correlated with clinicopathologic characteristics. RESULTS. The fraction of cells staining positively with caPCNA antibody in prostatic adenocarcinoma (mean, 23%) was significantly higher than that in benign prostatic epithelium (mean, 2%; P<0.001) or high-grade prostatic intraepithelial neoplasia (PIN) (mean, 6%; P<0.05). Moreover, the intensity of caPCNA expression in prostatic adenocarcinoma (mean, 2.9) was significantly higher than that in benign prostatic tissue (mean, 0.7; P<0.001) or high-grade PIN (mean, 2.0; P<0.001). Benign prostatic epithelium showed only minimal or negative reactivity. There was significant correlation between the percentage of caPCNA expression and primary Gleason grade (P=0.01), and with Gleason score (P=0.02). Adenocarcinomas with positive vascular invasion had a significantly higher percentage of cells staining with caPCNA antibody (P<0.0001) and a higher intensity of caPCNA expression (P=0.04). CONCLUSIONS. Our data indicate that increased expression of the cancer-associated isoform of PCNA is common in prostatic adenocarcinoma and its precursor and may be a useful biomarker.

Original languageEnglish
Pages (from-to)748-754
Number of pages7
JournalProstate
Volume71
Issue number7
DOIs
StatePublished - May 15 2011

Fingerprint

Prostatic Intraepithelial Neoplasia
Proliferating Cell Nuclear Antigen
Prostatic Neoplasms
Adenocarcinoma
Antibodies
Anti-Idiotypic Antibodies
Neoplasms
Epithelium
Staining and Labeling
Neoplasm Grading
Prostatectomy
DNA Replication
DNA Repair
Blood Vessels
Prostate
Protein Isoforms
Biomarkers
Rabbits

Keywords

  • Biomarkers
  • Carcinogenesis
  • Gleason grading
  • High-grade prostatic intraepithelial neoplasia (PIN)
  • Neoplasia
  • Progression
  • Proliferating cell nuclear antigen (PCNA)
  • Prostate
  • Targeted therapy

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

@article{00d0e02bf6b24f1cb4da4f9629a8e64b,
title = "Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer",
abstract = "BACKGROUND. Proliferating cell nuclear antigen (PCNA) plays an important role in DNA replication and repair. The expression and potential utility of this marker in prostatic neoplasia is uncertain. With the development of this new caPCNA selective antibody, we explored the potential utility of this marker in prostate cancer. METHODS. Using a traditional primary Fab2′ rabbit anti-caPCNA antibody-HRP conjugated secondary anti-Fab2′ antibody format, the expression of the caPCNA was analyzed in prostate tissue from 89 radical prostatectomy specimens. The caPCNA expression was correlated with clinicopathologic characteristics. RESULTS. The fraction of cells staining positively with caPCNA antibody in prostatic adenocarcinoma (mean, 23{\%}) was significantly higher than that in benign prostatic epithelium (mean, 2{\%}; P<0.001) or high-grade prostatic intraepithelial neoplasia (PIN) (mean, 6{\%}; P<0.05). Moreover, the intensity of caPCNA expression in prostatic adenocarcinoma (mean, 2.9) was significantly higher than that in benign prostatic tissue (mean, 0.7; P<0.001) or high-grade PIN (mean, 2.0; P<0.001). Benign prostatic epithelium showed only minimal or negative reactivity. There was significant correlation between the percentage of caPCNA expression and primary Gleason grade (P=0.01), and with Gleason score (P=0.02). Adenocarcinomas with positive vascular invasion had a significantly higher percentage of cells staining with caPCNA antibody (P<0.0001) and a higher intensity of caPCNA expression (P=0.04). CONCLUSIONS. Our data indicate that increased expression of the cancer-associated isoform of PCNA is common in prostatic adenocarcinoma and its precursor and may be a useful biomarker.",
keywords = "Biomarkers, Carcinogenesis, Gleason grading, High-grade prostatic intraepithelial neoplasia (PIN), Neoplasia, Progression, Proliferating cell nuclear antigen (PCNA), Prostate, Targeted therapy",
author = "Xiaoyan Wang and Hickey, {Robert J.} and Malkas, {Linda H.} and Michael Koch and Lang Li and Shaobo Zhang and George Sandusky and David Grignon and John Eble and Liang Cheng",
year = "2011",
month = "5",
day = "15",
doi = "10.1002/pros.21291",
language = "English",
volume = "71",
pages = "748--754",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer

AU - Wang, Xiaoyan

AU - Hickey, Robert J.

AU - Malkas, Linda H.

AU - Koch, Michael

AU - Li, Lang

AU - Zhang, Shaobo

AU - Sandusky, George

AU - Grignon, David

AU - Eble, John

AU - Cheng, Liang

PY - 2011/5/15

Y1 - 2011/5/15

N2 - BACKGROUND. Proliferating cell nuclear antigen (PCNA) plays an important role in DNA replication and repair. The expression and potential utility of this marker in prostatic neoplasia is uncertain. With the development of this new caPCNA selective antibody, we explored the potential utility of this marker in prostate cancer. METHODS. Using a traditional primary Fab2′ rabbit anti-caPCNA antibody-HRP conjugated secondary anti-Fab2′ antibody format, the expression of the caPCNA was analyzed in prostate tissue from 89 radical prostatectomy specimens. The caPCNA expression was correlated with clinicopathologic characteristics. RESULTS. The fraction of cells staining positively with caPCNA antibody in prostatic adenocarcinoma (mean, 23%) was significantly higher than that in benign prostatic epithelium (mean, 2%; P<0.001) or high-grade prostatic intraepithelial neoplasia (PIN) (mean, 6%; P<0.05). Moreover, the intensity of caPCNA expression in prostatic adenocarcinoma (mean, 2.9) was significantly higher than that in benign prostatic tissue (mean, 0.7; P<0.001) or high-grade PIN (mean, 2.0; P<0.001). Benign prostatic epithelium showed only minimal or negative reactivity. There was significant correlation between the percentage of caPCNA expression and primary Gleason grade (P=0.01), and with Gleason score (P=0.02). Adenocarcinomas with positive vascular invasion had a significantly higher percentage of cells staining with caPCNA antibody (P<0.0001) and a higher intensity of caPCNA expression (P=0.04). CONCLUSIONS. Our data indicate that increased expression of the cancer-associated isoform of PCNA is common in prostatic adenocarcinoma and its precursor and may be a useful biomarker.

AB - BACKGROUND. Proliferating cell nuclear antigen (PCNA) plays an important role in DNA replication and repair. The expression and potential utility of this marker in prostatic neoplasia is uncertain. With the development of this new caPCNA selective antibody, we explored the potential utility of this marker in prostate cancer. METHODS. Using a traditional primary Fab2′ rabbit anti-caPCNA antibody-HRP conjugated secondary anti-Fab2′ antibody format, the expression of the caPCNA was analyzed in prostate tissue from 89 radical prostatectomy specimens. The caPCNA expression was correlated with clinicopathologic characteristics. RESULTS. The fraction of cells staining positively with caPCNA antibody in prostatic adenocarcinoma (mean, 23%) was significantly higher than that in benign prostatic epithelium (mean, 2%; P<0.001) or high-grade prostatic intraepithelial neoplasia (PIN) (mean, 6%; P<0.05). Moreover, the intensity of caPCNA expression in prostatic adenocarcinoma (mean, 2.9) was significantly higher than that in benign prostatic tissue (mean, 0.7; P<0.001) or high-grade PIN (mean, 2.0; P<0.001). Benign prostatic epithelium showed only minimal or negative reactivity. There was significant correlation between the percentage of caPCNA expression and primary Gleason grade (P=0.01), and with Gleason score (P=0.02). Adenocarcinomas with positive vascular invasion had a significantly higher percentage of cells staining with caPCNA antibody (P<0.0001) and a higher intensity of caPCNA expression (P=0.04). CONCLUSIONS. Our data indicate that increased expression of the cancer-associated isoform of PCNA is common in prostatic adenocarcinoma and its precursor and may be a useful biomarker.

KW - Biomarkers

KW - Carcinogenesis

KW - Gleason grading

KW - High-grade prostatic intraepithelial neoplasia (PIN)

KW - Neoplasia

KW - Progression

KW - Proliferating cell nuclear antigen (PCNA)

KW - Prostate

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=79953689580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953689580&partnerID=8YFLogxK

U2 - 10.1002/pros.21291

DO - 10.1002/pros.21291

M3 - Article

VL - 71

SP - 748

EP - 754

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 7

ER -